DE60032275D1 - Verfahren und Zwischenprodukte zur Herstellung von Antikrebsmitteln - Google Patents

Verfahren und Zwischenprodukte zur Herstellung von Antikrebsmitteln

Info

Publication number
DE60032275D1
DE60032275D1 DE60032275T DE60032275T DE60032275D1 DE 60032275 D1 DE60032275 D1 DE 60032275D1 DE 60032275 T DE60032275 T DE 60032275T DE 60032275 T DE60032275 T DE 60032275T DE 60032275 D1 DE60032275 D1 DE 60032275D1
Authority
DE
Germany
Prior art keywords
intermediates
processes
production
anticancer agents
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032275T
Other languages
English (en)
Other versions
DE60032275T2 (de
Inventor
Richard Shelton Lehner
Timothy Norris
Dinos Paul Santafianos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
OSI Pharmaceuticals LLC
Original Assignee
Pfizer Products Inc
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc, OSI Pharmaceuticals LLC filed Critical Pfizer Products Inc
Publication of DE60032275D1 publication Critical patent/DE60032275D1/de
Application granted granted Critical
Publication of DE60032275T2 publication Critical patent/DE60032275T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60032275T 1999-03-31 2000-03-20 Verfahren und Zwischenprodukte zur Herstellung von Antikrebsmitteln Expired - Lifetime DE60032275T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31
US127072P 1999-03-31

Publications (2)

Publication Number Publication Date
DE60032275D1 true DE60032275D1 (de) 2007-01-25
DE60032275T2 DE60032275T2 (de) 2007-07-12

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032275T Expired - Lifetime DE60032275T2 (de) 1999-03-31 2000-03-20 Verfahren und Zwischenprodukte zur Herstellung von Antikrebsmitteln

Country Status (50)

Country Link
US (1) US6476040B1 (de)
EP (1) EP1044969B1 (de)
JP (2) JP3420549B2 (de)
KR (2) KR100430210B1 (de)
CN (2) CN100351242C (de)
AP (2) AP1655A (de)
AR (1) AR018705A1 (de)
AT (1) ATE348098T1 (de)
AU (2) AU781402B2 (de)
BG (1) BG65194B1 (de)
BR (1) BRPI0001486B8 (de)
CA (2) CA2302965C (de)
CO (1) CO5160273A1 (de)
CR (1) CR6165A (de)
CZ (1) CZ299426B6 (de)
DE (1) DE60032275T2 (de)
DK (1) DK1044969T3 (de)
DZ (1) DZ3030A1 (de)
EA (3) EA005892B1 (de)
EE (1) EE04589B1 (de)
EG (1) EG22506A (de)
ES (1) ES2278578T3 (de)
GE (1) GEP20022653B (de)
GT (1) GT200000037A (de)
HK (1) HK1029790A1 (de)
HR (1) HRP20000182B1 (de)
HU (1) HU227698B1 (de)
ID (1) ID25427A (de)
IL (2) IL135245A0 (de)
IS (1) IS2468B (de)
MA (1) MA25087A1 (de)
MY (1) MY136270A (de)
NO (2) NO321952B1 (de)
NZ (2) NZ503683A (de)
OA (1) OA11335A (de)
PA (1) PA8491901A1 (de)
PE (1) PE20001599A1 (de)
PL (1) PL339330A1 (de)
PT (1) PT1044969E (de)
RS (1) RS49836B (de)
SG (2) SG121687A1 (de)
SK (1) SK287339B6 (de)
SV (1) SV2002000047A (de)
TN (1) TNSN00064A1 (de)
TR (1) TR200000837A2 (de)
TW (1) TW553939B (de)
UA (2) UA70928C2 (de)
UY (1) UY26086A1 (de)
YU (1) YU13200A (de)
ZA (1) ZA200001586B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1408980A4 (de) 2001-06-21 2004-10-20 Ariad Pharma Inc Neue chinazoline und ihre verwendungszwecke
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
PL1667991T3 (pl) 2003-09-16 2008-12-31 Astrazeneca Ab Pochodne chinazoliny jako inhibitory kinazy tyrozynowej
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
KR20080095915A (ko) * 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
JPWO2006090930A1 (ja) 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規併用
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
ES2556173T3 (es) * 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
EP2054393A1 (de) 2006-07-28 2009-05-06 Synthon B.V. Kristallines erlotinib
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
PT2170844T (pt) * 2007-02-21 2016-08-05 Natco Pharma Ltd Novos polimorfos de cloridrato de erlotinib e método de preparação
CA2682013C (en) 2007-04-04 2015-06-30 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
WO2009025875A1 (en) * 2007-08-23 2009-02-26 Plus Chemicals Sa Stable formulations of crystalline erlotinib hcl
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
JP2011516426A (ja) * 2008-03-28 2011-05-26 コンサート ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体および治療方法
CA2730226A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
EA026425B1 (ru) 2009-01-16 2017-04-28 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
US8952022B2 (en) 2010-07-23 2015-02-10 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) * 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
BR112013021941B1 (pt) 2011-04-18 2022-11-16 Eisai R & D Management Co., Ltd Agente terapêutico para tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
DE69522717T2 (de) * 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
ATE295839T1 (de) 1998-04-29 2005-06-15 Osi Pharm Inc N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat

Also Published As

Publication number Publication date
IS2468B (is) 2008-12-15
HK1029790A1 (en) 2001-04-12
PE20001599A1 (es) 2001-01-18
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
HU0001353D0 (en) 2000-06-28
HUP0001353A3 (en) 2002-01-28
EP1044969B1 (de) 2006-12-13
GT200000037A (es) 2001-09-21
NO321952B1 (no) 2006-07-24
SG115536A1 (en) 2005-10-28
GEP20022653B (en) 2002-03-25
EA200000274A2 (ru) 2000-10-30
HRP20000182A2 (en) 2001-04-30
DZ3030A1 (fr) 2004-03-27
SK287339B6 (sk) 2010-07-07
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
ATE348098T1 (de) 2007-01-15
BR0001486A (pt) 2001-05-02
NO20054715L (no) 2000-10-02
TR200000837A2 (tr) 2000-11-21
EA200201245A1 (ru) 2003-04-24
NZ512818A (en) 2003-01-31
EA004654B1 (ru) 2004-06-24
YU13200A (sh) 2002-10-18
JP4074509B2 (ja) 2008-04-09
CO5160273A1 (es) 2002-05-30
CA2302965C (en) 2004-02-17
AU2005201494A1 (en) 2005-05-05
AU781402B2 (en) 2005-05-19
ZA200001586B (en) 2001-10-01
JP3420549B2 (ja) 2003-06-23
NO20001648D0 (no) 2000-03-30
EG22506A (en) 2003-03-31
EP1044969A2 (de) 2000-10-18
CZ299426B6 (cs) 2008-07-23
ID25427A (id) 2000-10-05
PL339330A1 (en) 2000-10-09
NZ503683A (en) 2001-09-28
CN1699350A (zh) 2005-11-23
CN1276370A (zh) 2000-12-13
BRPI0001486B1 (pt) 2019-01-29
BG104278A (en) 2001-08-31
EA005561B1 (ru) 2005-04-28
OA11335A (en) 2003-12-10
EA200201244A1 (ru) 2003-04-24
PT1044969E (pt) 2007-05-31
CA2427221C (en) 2008-09-16
IS5411A (is) 2000-10-02
PA8491901A1 (es) 2001-12-14
CZ20001155A3 (cs) 2001-03-14
KR100430209B1 (ko) 2004-05-03
NO20001648L (no) 2000-10-02
EA005892B1 (ru) 2005-06-30
SV2002000047A (es) 2002-01-23
SG121687A1 (en) 2006-05-26
SK4442000A3 (en) 2000-10-09
BRPI0001486B8 (pt) 2021-05-25
CR6165A (es) 2008-10-10
JP2003176274A (ja) 2003-06-24
KR100430210B1 (ko) 2004-05-03
CA2302965A1 (en) 2000-09-30
MY136270A (en) 2008-09-30
UA70928C2 (uk) 2004-11-15
CN100351242C (zh) 2007-11-28
TW553939B (en) 2003-09-21
EE200000255A (et) 2000-12-15
ES2278578T3 (es) 2007-08-16
EA200000274A3 (ru) 2003-02-27
HU227698B1 (en) 2011-12-28
CN1215061C (zh) 2005-08-17
DK1044969T3 (da) 2007-04-23
IL135245A0 (en) 2001-05-20
KR20020084903A (ko) 2002-11-13
BG65194B1 (bg) 2007-06-29
CA2427221A1 (en) 2000-09-30
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
UA80955C2 (en) 2007-11-26
JP2000290262A (ja) 2000-10-17
EP1044969A3 (de) 2000-11-29
DE60032275T2 (de) 2007-07-12
KR20010014658A (ko) 2001-02-26
UY26086A1 (es) 2000-10-31
AR018705A1 (es) 2001-11-28
RS49836B (sr) 2008-08-07
AU2005201494B2 (en) 2008-02-07
HUP0001353A2 (hu) 2001-05-28
AP1655A (en) 2006-09-01
US6476040B1 (en) 2002-11-05
MA25087A1 (fr) 2000-10-01
EE04589B1 (et) 2006-02-15
AP1265A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
DE60032275D1 (de) Verfahren und Zwischenprodukte zur Herstellung von Antikrebsmitteln
DE50000852D1 (de) Verfahren zur Herstellung von Aminen
DE60008315D1 (de) Verfahren zur Herstellung von Methylchlorid
DE60120685D1 (de) Verfahren zur herstellung von dihydroxyestern und ihren derivaten
DE60019747D1 (de) Verfahren zur herstellung von fluorolefinen
DE60024210D1 (de) Verfahren zur Herstellung von Zahnrädern
DE60009828D1 (de) Luftreifen und verfahren zur herstellung des luftreifens
DE60033941D1 (de) Neuartiges verfahren zur herstellung von l-epi-2-inosose und neuartiges verfahren zur herstellung von epi-inositol
DE60029697D1 (de) Febrifugin und ispofebrifugin und verfahren zur herstellung der beiden
DE60032894D1 (de) Verfahren zur herstellung von stadtgas
ATA218299A (de) Verfahren zur herstellung von oxindolen
DE60024372D1 (de) Verfahren zur Herstellung von Tetraorganooxysilanen
DE60039688D1 (de) Verfahren zur herstellung von uhrarmbandteilen
DE69916332D1 (de) Verfahren zur herstellung von etheraminalkoxylaten
DE60002538D1 (de) Verfahren zur Herstellung von Cyclododecanon und Cyclododecanol
DE69922440D1 (de) Verfahren und Zwischenprodukte zur Herstellung von 2,3-Pyridindicarboxylatderivaten
DE60031231D1 (de) Verfahren zur Herstellung von 2-Alkyl-4-Isothiazolin-3-onen
DE50010478D1 (de) Verfahren zur herstellung von polyamiden
DE59800130D1 (de) Verfahren zur Herstellung von Organosilazanen
DE60004119D1 (de) Verfahren zur Herstellung von Pentaacetyl-beta-D-Glucopyranose
DE60023802D1 (de) Verfahren zur Herstellung des Lykopens und Zwischenprodukte davon
DE50000038D1 (de) Verfahren zur Herstellung von Organochlorsilanen
DE60005252D1 (de) Verfahren zur Herstellung von Malononitril
DE50008921D1 (de) Verfahren zur herstellung von blockweichschaumpolyolen
DE60043559D1 (de) Verfahren zur Herstellung von Elektroden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition